- Trials with a EudraCT protocol (75)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (13)
75 result(s) found for: Myositis.
Displaying page 1 of 4.
EudraCT Number: 2015-001411-12 | Sponsor Protocol Number: CBYM338B2203E1 | Start Date*: 2015-11-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis | |||||||||||||
Medical condition: Sporadic Inclusion Body Myositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) DK (Completed) GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000705-23 | Sponsor Protocol Number: CBYM338B2203 | Start Date*: 2014-02-09 | |||||||||||
Sponsor Name:Novartis Farma SpA | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52... | |||||||||||||
Medical condition: Sporadic Inclusion Body Myositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) NL (Completed) DE (Completed) BE (Completed) GB (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008208-42 | Sponsor Protocol Number: 08/0168 | Start Date*: 2009-06-26 | |||||||||||
Sponsor Name:UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit | |||||||||||||
Full Title: A Randomised, Double-Blind Placebo-Controlled Pilot Study Assessing the Safety and Tolerability of Arimoclomol in Adult with Sporadic Inclusion Body Myositis | |||||||||||||
Medical condition: The research project proposes to investigate Sporadic Inclusion Body Myositis (IBM). IBM is the commonest acquired disease of muscle affecting people aged 50 years and over. It is a progressive and... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000391-15 | Sponsor Protocol Number: AIFA-2016-02364869 | Start Date*: 2018-06-05 | |||||||||||||||||||||
Sponsor Name:Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia | |||||||||||||||||||||||
Full Title: Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis | |||||||||||||||||||||||
Medical condition: Myositis (dermatomyositis [DM] or polymyositis [PM]) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002286-17 | Sponsor Protocol Number: INCB00928-201 | Start Date*: 2022-04-19 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | |||||||||||||
Medical condition: Fibrodysplasia ossificans progressiva | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000692-39 | Sponsor Protocol Number: IVY | Start Date*: 2023-06-19 | |||||||||||
Sponsor Name:Amsterdam University Medical Center | |||||||||||||
Full Title: Safety, tolerability and immunogenicity of intradermal mRNA SARS-CoV2 vaccination in patients with Fibrodysplasia Ossificans Progressiva | |||||||||||||
Medical condition: Fibrodyplasia Ossificans Progressiva (FOP) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000880-40 | Sponsor Protocol Number: R2477-FOP-2175 | Start Date*: 2022-08-29 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressiva | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FI (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002496-28 | Sponsor Protocol Number: PVO-1A-202 | Start Date*: 2015-11-13 | |||||||||||
Sponsor Name:Clementia Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva ... | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and abnormal heterotopic ossificat... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001453-17 | Sponsor Protocol Number: PVO-1A-201 | Start Date*: 2015-07-07 | |||||||||||
Sponsor Name:Clementia Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia O... | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and abnormal heterotopic ossificat... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003324-20 | Sponsor Protocol Number: STOPFOP1 | Start Date*: 2020-01-08 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: Saracatinib trial TO Prevent FOP | |||||||||||||
Medical condition: Fibrodyplasia Ossificans Progressiva (FOP) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002244-70 | Sponsor Protocol Number: CLIN-60120-452 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Ipsen Pharma SAS | |||||||||||||
Full Title: Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years with Fibrodysplasia Ossi... | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002541-29 | Sponsor Protocol Number: PVO-1A-301 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:Clementia Pharmaceuticals Inc | |||||||||||||
Full Title: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) ES (Ongoing) DE (Completed) FR (Completed) NL (Ongoing) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002269-77 | Sponsor Protocol Number: IM101611 | Start Date*: 2017-08-07 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in ... | |||||||||||||
Medical condition: Idiopathic Inflammatory Myopathy (IIM; eg, Dermatomyositis [DM], Polymyositis [PM], autoimmune necrotizing myopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) SE (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002526-36 | Sponsor Protocol Number: PVO-1A-204 | Start Date*: 2022-07-05 | |||||||||||
Sponsor Name:Clementia Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label, Efficacy and Safety Study of an RARγ-Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects with Fibrodysplasia Ossificans Progressiva (FOP) | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and abnormal heterotopic ossificat... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000078-65 | Sponsor Protocol Number: Rituximab | Start Date*: 2007-01-17 | |||||||||||
Sponsor Name:Karolinska University Hospital | |||||||||||||
Full Title: Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) | |||||||||||||
Medical condition: Adult polymyositis or adult dermatomyositis or juvenile dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000749-11 | Sponsor Protocol Number: IBM-OLE | Start Date*: 2019-10-09 | |||||||||||
Sponsor Name:Orphazyme A/S | |||||||||||||
Full Title: An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed start of arimoclomol in patients with sporadic inclusion body myositis who have completed the IBM4... | |||||||||||||
Medical condition: Sporadic Inclusion Body Myositis (sIBM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005035-33 | Sponsor Protocol Number: R2477-FOP-1623 | Start Date*: 2017-08-15 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progres... | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004410-13 | Sponsor Protocol Number: 3401 | Start Date*: 2008-03-12 | ||||||||||||||||
Sponsor Name:Institute od Rheumatology Prague | ||||||||||||||||||
Full Title: A PROSPECTIVE, RANDOMISED, ASSESSOR-BLIND, MULTICENTER STUDY OF EFFICACY AND SAFETY OF COMBINED TREATMENT OF METHOTREXATE + GLUCOCORTICOIDS VERSUS GLUCOCORTICOIDS ALONE IN PATIENTS WITH POLYMYOSITI... | ||||||||||||||||||
Medical condition: active polymyositis, dermatomyositis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) SE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001710-37 | Sponsor Protocol Number: NL73727 | Start Date*: 2021-05-26 |
Sponsor Name:Academisch Medisch Centrum | ||
Full Title: Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial. | ||
Medical condition: idiopathic inflammatory myopathies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004903-33 | Sponsor Protocol Number: IBM4809 | Start Date*: 2018-06-18 | |||||||||||
Sponsor Name:Orphazyme A/S | |||||||||||||
Full Title: Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) A Randomized, Double-blind, Placebo-Controlled Trial | |||||||||||||
Medical condition: Sporadic Inclusion Body Myositis (sIBM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
